References
- Steyerberg EW, Harrell FE. Prediction models need appropriate internal, internal–external, and external validation. Journal of Clinical Epidemiology. 2016; 69: 245–7. DOI: 10.1016/j.jclinepi.2015.04.005
- World Health Organization (WHO).
Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk . World Health Organization; 2007. - Giampaoli S, Palmieri L, Mattiello A, Panico S. Definition of high risk individuals to optimise strategies for primary prevention of cardiovascular diseases. Nutrition, Metabolism and Cardiovascular Diseases. 2005; 15(1): 79–85. DOI: 10.1016/j.numecd.2004.12.001
- Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2014; 63(25 Part B): 2935–59. DOI: 10.1161/01.cir.0000437741.48606.98
- World Health Organization (WHO).
Global action plan for the prevention and control of noncommunicable diseases 2013–2020 . World Health Organization; 2013. - Eslami A, Lotfaliany M, Akbarpour S, Azizi F, Hadaegh F. Trend of cardiovascular risk factors in the older Iranian population: 2002–2014. Geriatrics & Gerontology International. 2018; 18(1): 130–7. DOI: 10.1111/ggi.13154
- Khosravi-Boroujeni H, Sarrafzadegan N, Sadeghi M, Roohafza H, Talaei M, Ng S-K, et al. Secular trend of metabolic syndrome and its components in a cohort of Iranian adults from 2001 to 2013. Metabolic Syndrome and Related Disorders. 2017; 15(3): 137–44.
- Noshad S, Abbasi M, Etemad K, Meysamie A, Afarideh M, Khajeh E, et al. Prevalence of metabolic syndrome in Iran: A 2011 update: 伊朗的代谢综合征患病率 : 2011 年更新数据. Journal of Diabetes. 2017; 9(5): 518–25. DOI: 10.1111/1753-0407.12438
- Kaptoge S, Pennells L, De Bacquer D, Cooney MT, Kavousi M, Stevens G, et al. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. The Lancet Global Health. 2019; 7(10): e1332–e45.
- Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139(25): e1082–e143. DOI: 10.1161/CIR.0000000000000698
- Yadav R, Yadav RK, Sarvottam K, Netam R. Framingham risk score and estimated 10-year cardiovascular disease risk reduction by a short-term yoga-based lifestyle intervention. The Journal of Alternative and Complementary Medicine. 2017; 23(9): 730–7. DOI: 10.1089/acm.2016.0309
- Mendis S. Cardiovascular risk assessment and management in developing countries. Vascular Health and Risk Management. 2005; 1(1): 15. DOI: 10.2147/vhrm.1.1.15.58933
- Baghbani-Oskouei A, Tohidi M, Asgari S, Ramezankhani A, Azizi F, Hadaegh F. Serum Lipids during 20 years in the Tehran Lipid and Glucose Study: Prevalence, trends and impact on non-communicable diseases. International Journal of Endocrinology and Metabolism. 2018; 16(4 Suppl). DOI: 10.5812/ijem.84750
- Jahangiri-Noudeh Y, Akbarpour S, Lotfaliany M, Zafari N, Khalili D, Tohidi M, et al. Trends in cardiovascular disease risk factors in people with and without diabetes mellitus: a Middle Eastern cohort study. PloS One. 2014; 9(12):
e112639 . DOI: 10.1371/journal.pone.0112639 - Rahmani F, Asgari S, Khalili D, Moeini ASH, Tohidi M, Azizi F, et al. National trends in cardiovascular health metrics among Iranian adults using results of three cross-sectional STEPwise approaches to surveillance surveys. Scientific Reports. 2021; 11(1): 1–11. DOI: 10.1038/s41598-020-79322-x
- Malekzadeh H, Lotfaliany M, Ostovar A, Hadaegh F, Azizi F, Yoosefi M, et al. Trends in cardiovascular risk factors in diabetic patients in comparison to general population in Iran: findings from National Surveys 2007–2016. Scientific Reports. 2020; 10(1): 1–10. DOI: 10.1038/s41598-020-68640-9
- Meysamie A, Ghalehtaki R, Ghodsi S, Esteghamati A, Mohammad K, Etemad K, et al. Trend of cigarette smoking in Iranian adult population from 2000 to 2011 based on four national surveys. Social Determinants of Health. 2017; 3(3): 148–59.
- Agaku IT, Odani S, Okuyemi KS, Armour B. Disparities in current cigarette smoking among US adults, 2002–2016. Tobacco Control. 2020; 29(3): 269–76. DOI: 10.1136/tobaccocontrol-2019-054948
- Prevention Control CfD. Vital signs: current cigarette smoking among adults aged≥ 18 years–United States, 2005–2010. MMWR Morbidity and Mortality Weekly Report. 2011; 60(35): 1207–12.
- Sharifi H, Ramezan KA, Falah TS, Sharif KB, Padyab M, Heydari GR. Public awareness about framework convention on tobacco control (FCTC) in Tehran; 2009.
- Amerzadeh M, Takian A. Reducing sugar, fat, and salt for prevention and control of noncommunicable diseases (NCDs) as an adopted health policy in Iran. Medical Journal of the Islamic Republic of Iran. 2020; 34: 136. DOI: 10.47176/mjiri.34.136
- Peymani P, Joulaie H, Zamiri N, Ahmadi SM, Dinarvand R, Hosseini H, et al. Iran’s experience on reduction of trans-fatty acid content in edible oils. Middle East J Sci Res. 2012; 11(9): 1207–11.
- Kheirandish M, Asgari S, Lotfaliany M, Bozorgmanesh M, Saadat N, Tohidi M, et al. Secular trends in serum lipid levels of a Middle Eastern adult population; 10 years follow up in Tehran lipid and glucose study. Lipids in Health and Disease. 2014; 13(1): 1–13. DOI: 10.1186/1476-511X-13-20
- Torabi P, Zare F, Shekholeslam R, Safavi S, (eds.)
Study of vegetable oil consumption in 15 pilot universities of Iran . 12th Nutritional Congress Tabriz; Iran; 2004. - Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. British Medical Journal. 1989; 298(6676): 784–8. DOI: 10.1136/bmj.298.6676.784
- Matheus ASdM, Tannus LRM, Cobas RA, Palma CCS, Negrato CA, Gomes MdB. Impact of diabetes on cardiovascular disease: an update. International Journal of Hypertension. 2013; 2013. DOI: 10.1155/2013/653789
- Esteghamati A, Larijani B, Aghajani MH, Ghaemi F, Kermanchi J, Shahrami A, et al. Diabetes in Iran: prospective analysis from first nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2016). Scientific Reports. 2017; 7(1): 1–10. DOI: 10.1038/s41598-017-13379-z
- Joseph P, Yusuf S, Lee SF, Ibrahim Q, Teo K, Rangarajan S, et al. Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world. Heart. 2018; 104(7): 581–7. DOI: 10.1136/heartjnl-2017-311609
- Pandya A, Weinstein MC, Gaziano TA. A comparative assessment of non-laboratory-based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population. PloS One. 2011; 6(5):
e20416 . DOI: 10.1371/journal.pone.0020416 - Lotfaliany M, Hadaegh F, Asgari S, Mansournia MA, Azizi F, Oldenburg B, et al. Non-invasive risk prediction models in identifying undiagnosed type 2 diabetes or predicting future incident cases in the Iranian population. Archives of Iranian Medicine. 2019; 22(3): 116–24.
- Asgari S, Lotfaliany M, Fahimfar N, Hadaegh F, Azizi F, Khalili D. The external validity and performance of the no-laboratory American Diabetes Association screening tool for identifying undiagnosed type 2 diabetes among the Iranian population. Primary Care Diabetes. 2020; 14(6): 672–7. DOI: 10.1016/j.pcd.2020.04.001
- Lotfaliany M, Hadaegh F, Mansournia MA, Azizi F, Oldenburg B, Khalili D. Performance of stepwise screening methods in identifying individuals at high risk of type 2 diabetes in an Iranian population. International Journal of Health Policy and Management; 2021. DOI: 10.34172/ijhpm.2021.22